Inger Nijhof
Overview
Explore the profile of Inger Nijhof including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smits F, Smits F, Groen K, Levin M, Stege C, Stege C, et al.
Blood
. 2024 Nov;
145(5):543-546.
PMID: 39576961
The level of frailty, according to the International Myeloma Working Group frailty index, is highly dynamic during antimyeloma treatment. Dynamic frailty assessment improved the prediction of survival and early mortality...
2.
Neri P, Nijhof I
Crit Rev Oncol Hematol
. 2023 Jun;
188:104041.
PMID: 37268176
Treatment of multiple myeloma (MM) has seen great advances in recent years, and a key contributor to this change has been the effective use of combination therapies, which have improved...
3.
In t Veld S, Arkani M, Post E, Antunes-Ferreira M, DAmbrosi S, Vessies D, et al.
Cancer Cell
. 2022 Sep;
40(9):999-1009.e6.
PMID: 36055228
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for...
4.
Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, et al.
Lancet Haematol
. 2021 Nov;
8(12):e934-e946.
PMID: 34756169
Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for infections and infection-related mortality. The risk for infection with SARS-CoV-2 virus and resulting mortality is...
5.
Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, et al.
Leukemia
. 2020 Aug;
35(1):31-44.
PMID: 32814840
Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an...
6.
Casneuf T, Adams 3rd H, van de Donk N, Abraham Y, Bald J, Vanhoof G, et al.
Leukemia
. 2020 May;
35(2):573-584.
PMID: 32457357
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune...
7.
Adams 3rd H, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, et al.
Cytometry A
. 2018 Dec;
95(3):279-289.
PMID: 30536810
Daratumumab is a CD38-targeted human monoclonal antibody with direct anti-myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated with daratumumab revealed cytotoxic T-cell...
8.
van der Wagen L, Te Boome L, Schiffler M, Nijhof I, Schoordijk M, van Dorp S, et al.
Bone Marrow Transplant
. 2018 Mar;
53(10):1255-1262.
PMID: 29549292
Sclerotic chronic graft vs. host disease (cGVHD) still has a large impact on morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We performed the first prospective study to...